Fulcrum Therapeutics Inc. (FULC) Misses Q3 EPS by 5c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
Fulcrum Therapeutics Reports Recent Business Highlights and Third Quarter 2020 Financial Results
November 10, 2020 7:00 AM ESTReDUX4 trial progressing; full data with losmapimod in facioscapulohumeral muscular dystrophy (FSHD) expected in 2Q 2021
 On track to begin dosing Phase 1 trial with FTX-6058 for sickle cell disease before YE 2020
 Cash runway into 2Q 2022
 Key appointments to management team
Conference call scheduled for 8:00 a.m. ET today
CAMBRIDGE, Mass., Nov. 10,... More
